Management of HIV Treatment Failure with Drug Resistance
When virologic failure is confirmed (HIV RNA >200 copies/mL), perform resistance testing immediately while the patient remains on the failing regimen, then promptly switch to a new active regimen guided by both current and all prior resistance test results. 1
Immediate Diagnostic Steps
Confirm virologic failure with a second HIV RNA measurement >200 copies/mL, then obtain resistance testing while the patient is still taking the failing regimen (or within 4 weeks of stopping) 1. Review the complete antiretroviral therapy (ART) history, all previous resistance test results, medication tolerability, co-medications, and adherence barriers before selecting the next regimen 1.
Second-Line Regimen Selection Based on Failing Drug Class
The choice of second-line therapy depends critically on which drug class failed initially:
If NNRTI-Based Regimen Failed
Use dolutegravir plus 2 NRTIs (with at least 1 active drug determined by genotypic testing) 1. This recommendation carries the highest evidence rating (AIa) and reflects superior outcomes compared to protease inhibitor alternatives.
If Integrase Inhibitor (InSTI)-Based Regimen Failed
Use a boosted protease inhibitor plus 2 NRTIs (with at least 1 active NRTI) 1. This is the recommended approach for initial InSTI treatment failure.
If Raltegravir or Elvitegravir Resistance Detected
Use dolutegravir 50 mg twice daily (not once daily) plus at least 1 fully active other agent 1. The twice-daily dosing is essential when first-generation InSTI resistance is present.
If Protease Inhibitor-Based Regimen Failed
This scenario is uncommon because virologic failure with resistance mutations is rare with PIs 1. Focus on adherence support or switch to an alternative regimen that improves adherence and tolerability rather than assuming resistance 1. If PI resistance is documented, use second-generation agents like darunavir/ritonavir 2.
Critical Management Principles
Never add a single active agent to a failing regimen 1. This is strongly contraindicated (evidence rating AIa) as it promotes further resistance development.
Do not switch from a boosted PI to a low genetic barrier drug (NNRTI or raltegravir) in patients with NRTI resistance mutations, even if virologically suppressed 1.
Avoid monotherapy with boosted PIs or dolutegravir under any circumstances 1.
Multiclass Resistance (3-Class Resistance)
When resistance spans three drug classes, construct the next regimen using drugs from new classes: fostemsavir (evidence rating AIb) or ibalizumab (evidence rating BII) with at least 1 additional active drug in an optimized regimen 1. Continue NRTIs like tenofovir/emtricitabine or lamivudine as they retain partial activity even with extensive resistance mutations 3.
Monitoring After Switch
Assess HIV viral load 1 month after switching regimens 1. This early monitoring allows rapid detection of inadequate response and prevents accumulation of additional resistance mutations.
Special Considerations for Persistent Virologic Failure
For patients unable to maintain adherence to oral ART despite extensive support, who have CD4 <200 cells/μL or AIDS-defining complications, and whose virus remains susceptible to both drugs, consider long-acting injectable cabotegravir plus rilpivirine every 4-8 weeks with intensive case management 3. This strategy has demonstrated superiority over oral therapy in randomized trials for patients with virologic failure and adherence challenges.
Common Pitfalls to Avoid
The most frequent cause of virologic failure is suboptimal adherence, not resistance 3. Before assuming resistance-driven failure, investigate adherence barriers, drug-drug interactions, and absorption issues. Many patients on contemporary dolutegravir or bictegravir-based regimens will have no detectable resistance at virologic failure 3.
Do not delay switching once resistance is confirmed—prompt transition prevents evolution of additional resistance mutations 2. The 2020 IAS-USA guidelines emphasize that confirmed virologic failure with identified resistance requires immediate regimen change 1.
For patients with hepatitis B co-infection, maintain tenofovir alafenamide or tenofovir disoproxil fumarate in the new regimen unless contraindicated, as switching away from these agents without alternative HBV therapy risks HBV reactivation 1.